*Read Disclaimer Sponsored Content | Unsubscribe
Hello!
New Alert: NanoViricides, Inc. (NYSE American: NNVC)
NNVC is our new NYSE breakout opportunity.
This has been a very big winner for you many times following our previous alerts.
We think it presents another compelling opportunity, as it did before.
Following our alert in March, the company rallied +53% in 2 months.
Before that, in January, NNVC rallied +35% in about a month.
Now, NNVC could be positioning for another big move higher.
Following our previous alert in June, the company has been building what looks to be a very solid base…
This is a chart where history suggests rallies are born.
NNVC could present increased upside potential.
In addition, the company has announced multiple developments recently.
NNVC is a NYSE listed "clinical stage company that is creating special purpose nanomaterials for antiviral therapy".
The Company's "novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc".
The "nanoviricides™ platform technology is yielding novel antiviral drug candidates against a number of challenging viral targets at a rapid pace".
NNVC's "most advanced candidate, NV-387, is an ultra-broad-spectrum antiviral with potential activity against most respiratory human pathogenic viruses - and more, because it emulates the attachment receptor family of sulfated proteoglycans that over 90% of human viruses utilize".
"The overall market size of NV-387 indications is estimated to be well in excess of $10 billion."
"NV-387 is designed to shape-shift upon binding to the virus particle, in the process disrupting the virus particle and making it incapable of infection, as a complete chemical nanomachine that destroys the virus".
"The revolutionary broad antiviral spectrum of NV-387 is reminiscent of the dawn of antibiotics to combat bacterial infections."
As the company further explains:
"Viruses are unlikely to escape NV-387 because no matter how much a virus evolves, it continues to utilize and require binding to sulfated proteoglycans - the very characteristic that NV-387 emulates."
"This solves the long-standing problem of antiviral medicines, that viruses escape them."
"Vaccines, antibodies and small chemical drugs are readily escaped by viruses as the viruses evolve in the field."
"This has been repeatedly observed during the recent COVID-19 pandemic, as well as in the course of most of the other viral epidemics including Influenza and HIV/AIDS."
Furthermore:
"Continued redevelopment or "updating" of vaccines necessitated by the viral escape or drift has recurrently cost billions of dollars every year for Influenza as well as COVID."
"NV-387 promises to make such costly endeavors unnecessary, once this drug is approved by regulatory bodies."
"NV-387 is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation for the Treatment of MPOX disease, in response to the continuing Public Health Emergency of International Concern in WHO African Region."
NNVC has "received preliminary approval of the clinical protocol and the study and now we are working diligently to finish and submit the clinical trial application".
Plus, "NV-387 was found to be highly effective against the "tripledemic" respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. NV-387 was found to be substantially superior to existing drugs, and even resulted in complete cure in the RSV animal study."
Further, "NV-387 has shown excellent effectiveness in lethal lung infection animal models relevant for Smallpox and MPox viruses".
Additionally, "NV-387 has shown excellent effectiveness in lethal lung infection in a humanized (hCD150+ knock-in) mouse model by the Measles virus. Cases of Measles have been rapidly rising in the developing world including USA, Canada, UK and European countries. Measles is an important health threat because the disease can lead to "immune amnesia", wiping out pre-developed immunity against other diseases, because it attacks the immune system itself."
Sadly, "At present, there are no generally approved drugs for the treatment of RSV, MPox, or Measles."
"The latter two are orphan diseases in the USA and will be eligible for earning a "Priority Review Voucher" (PRV) from the US FDA plus several years of market exclusivity upon approval. Each PRV is currently thought to be worth $150 million to $350 million as a tradable asset."
Additionally, "NV-387's success in treating MPox is expected to make it feasible to achieve US FDA regulatory approval as a Smallpox therapeutic, a much-needed drug for the US Bioterrorism defense strategy, with potential lucrative US Government and International contracts for stockpiling in the range of several hundred millions of dollars, assuming NV-387 is successful in a Phase II clinical trial for MPox treatment".
Importantly:
- "NV-387 is expected to become an "emperic therapy" for viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections."
- "NV-387 would be the first ever drug enabling emperic antiviral therapy, and would be potentially as revolutionary to antiviral therapy as antibiotics have been to anti-bacterial therapy."
Emperic therapy means when the patient presents to the doctor, immediately the antiviral drug can be prescribed and started without having to wait for discriminating test results as to which virus is causing the infection.
This has "tremendous benefits since antiviral drugs are most effective when given as early as possible upon viral infection".
In addition, NNVC has "developed a clinical-ready pan-herpesvirus drug candidate, NV-HHV-1 that has shown activity against HSV-1, HSV-2 and VZV, and is expected to have activity against CMV, HHV-6, and HHV-8 as well".
NNVC has also "developed an anti-HIV drug candidate, NV-HIV-1, that has shown strong efficacy in SCID-hu-Thy-Liv animal model of HIV infection. NV-HHV-1 mimics the landing site on cellular CD4 that is required for all HIV viruses to cause cellular infection. Thus, HIV, despite constant changes, will be unable to escape NV-HHV-1".
"NanoViricide Platform Enables Drug Rescue, Oral Drug Delivery, and Zip-Code Specific Delivery":
- "Oral drug delivery of small chemicals, peptides (such as the GLP-a obesity drugs), and proteins is feasible by encapsulation of the guest drug into the nanoviricide polymeric micelle. The encapsulation protects the guest from metabolism thereby enabling effective drug delivery."
- "Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work."
- "Going another step further, the nanoviricide platform technology can be customized to enable zip-code-like specific delivery of encapsulated drugs to specific tissues (e.g. non-liver targeted delivery),, cells (e.g. cancer-cell specific delivery sparing normal cells), bacteria, or viruses (e.g. NV-HHV-1, NV-HIV-1) in a fully synthetic chemistry based, scalable technology stack."
The company has announced multiple accomplishments recently.
In July, the company announced:
- "There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate"
- "Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides"
- "WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides"
- "Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides"
- "NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value"
- "Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides"
In August, the company announced:
"A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials"
As the company states:
- "Thus NV-387 treatment could have a strong impact in the treatment of cancer patients in remission who suffer from a viral infection that could lead to the cancer returning with metastasis to multiple sites in the body."
Here are some of the comments from this press release:
"NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place," said Anil R. Diwan, Ph.D., President and Chairman of the Company, adding, "We have found that NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on these reported studies."
Most recently, the company announced:
"NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025"
"SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Wednesday, September 17th, at 12:30pm at the Life Science Executive Partnering ("LSX") World Congress 2025 in Boston, MA."
NNVC could be in a position to experience increased growth.
Make sure to do your own due diligence.
Sources: PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, Website, Chart
Happy Trading!
AwesomeStocks
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
